Loading clinical trials...
Loading clinical trials...
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Conditions
Interventions
QBW251
Placebo
Locations
16
United States
Novartis Investigative Site
Birmingham, Alabama, United States
Novartis Investigative Site
Fullerton, California, United States
Novartis Investigative Site
Waterbury, Connecticut, United States
Novartis Investigative Site
Clearwater, Florida, United States
Novartis Investigative Site
Port Orange, Florida, United States
Novartis Investigative Site
Tampa, Florida, United States
Start Date
April 30, 2015
Primary Completion Date
December 27, 2016
Completion Date
January 23, 2017
Last Updated
January 5, 2021
NCT06612476
NCT02442206
NCT00496470
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions